The impact of aripiprazole on neurocognitive function in individuals at clinical high risk for psychosis: A comparison with olanzapine and non-antipsychotic treatment.

ABSTRACT:

Background

Clinical high risk for psychosis (CHR) is often managed with antipsychotic medications, but their effects on neurocognitive performance and clinical outcomes remain insufficiently explored. This study investigates the association between aripiprazole and olanzapine use and cognitive and clinical outcomes in CHR individuals, compared to those receiving no antipsychotic treatment.

Methods

A retrospective analysis was conducted on 127 participants from the Shanghai At Risk for Psychosis (SHARP) cohort, categorized into three groups: aripiprazole, olanzapine, and no antipsychotic treatment. Neurocognitive performance was evaluated using the MATRICS Consensus Cognitive Battery (MCCB), while clinical symptoms were assessed through the Structured Interview for Prodromal

SUBMITTER: Zeng J 

PROVIDER: S-EPMC12188342 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature